MannKind has the raw data from the 171 study now and will have the data from the Type 2 study shortly. It will take them until August to crunch the numbers and be ready to report the top line results. Al said they would delay the August quarterly conference call until those top line results are made public so they can be discussed on the call. The independent monitoring company just collected the raw data and monitored patient and physician compliance. MannKind analyzes the data.